In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Supplements, food and fibres work differently, targeting your stomach directly and making you fuller faster, and for longer
GLP-1 Agonists slow down gut motility which is probably advantageous with eating as it allows time for the breakdown and absorption of nutrients from food in the small intestine
Hydroxocobalamin 1mg/ml Solution for Injection Patient Information Leaflet
Visceral fat why its a distinct research focus Visceral fat the adipose tissue stored around internal organs rather than beneath the skin is treated as a distinct research focus because its metabolically more active than subcutaneous fat and has been linked in the literature to a different set of metabolic markers
Do not inject twice in one week to 'make up' the missed dose, as this can increase side effects like nausea or stomach discomfort